MBX Biosciences (NASDAQ:MBX) Sees Unusually-High Trading Volume – What’s Next?

Shares of MBX Biosciences, Inc. (NASDAQ:MBX) saw unusually-high trading volume on Tuesday . Approximately 865,252 shares changed hands during mid-day trading, an increase of 37% from the previous session’s volume of 631,091 shares.The stock last traded at $30.4950 and had previously closed at $31.30.

Wall Street Analysts Forecast Growth

MBX has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of MBX Biosciences in a report on Thursday, January 22nd. Lifesci Capital upgraded shares of MBX Biosciences to a “strong-buy” rating in a report on Tuesday, March 31st. Barclays began coverage on shares of MBX Biosciences in a report on Tuesday, January 27th. They issued an “overweight” rating and a $66.00 price target on the stock. Wall Street Zen raised shares of MBX Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Finally, TD Cowen reaffirmed a “buy” rating on shares of MBX Biosciences in a report on Thursday, March 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.56.

MBX Biosciences Stock Down 5.9%

The company’s 50 day moving average price is $33.20 and its 200 day moving average price is $28.68. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -12.38 and a beta of 1.25.

MBX Biosciences (NASDAQ:MBX) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.15.

Insider Activity at MBX Biosciences

In other MBX Biosciences news, CEO P. Kent Hawryluk bought 18,500 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average cost of $28.41 per share, for a total transaction of $525,585.00. Following the completion of the transaction, the chief executive officer directly owned 486,777 shares of the company’s stock, valued at approximately $13,829,334.57. This trade represents a 3.95% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 52.19% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP acquired a new position in MBX Biosciences during the third quarter valued at $1,488,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in MBX Biosciences during the third quarter valued at $498,000. Resolute Capital Asset Partners LLC acquired a new position in MBX Biosciences during the second quarter valued at $567,000. Walleye Capital LLC lifted its position in MBX Biosciences by 116.5% during the second quarter. Walleye Capital LLC now owns 70,333 shares of the company’s stock valued at $802,000 after purchasing an additional 37,843 shares during the period. Finally, Baker BROS. Advisors LP acquired a new position in MBX Biosciences during the third quarter valued at $4,861,000.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.